GSK to acquire Aiolos Bio for $1bn
Betsy Goodfellow | January 9, 2024 | News story | Business Services | Aiolos Bio, GSK, Pharmacy, acquisition
GSK and Aiolos Bio have announced that they have entered into an agreement for GSK to acquire Aiolos for an initial $1bn upfront payment along with up to $400m in success-based regulatory milestone payments.
Aiolos is a clinical-stage biopharmaceutical company with a focus on the treatment of patients with certain respiratory and inflammatory conditions.
This acquisition will allow GSK to access Aiolos’s AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody which is ready to enter phase 2 clinical development for the treatment of adult patients with asthma, although there are other potential additional indications such as chronic rhinosinusitis with nasal polyps.
By gaining AIO-001, GSK intends to expand its respiratory portfolio to provide an option of a biologic to treat a wider selection of patients living with asthma.
Tony Wood, chief scientific officer at GSK, commented: “We have a proud heritage and deep development expertise in respiratory medicines, especially addressing diseases driven by IL-5 with high levels of eosinophils or high T2 inflammation. Adding AIO-001, a potentially best-in-class medicine targeting the TSLP pathway, could expand the reach of our current respiratory biologics portfolio, including to the 40% of severe asthma patients with low T2 inflammation where treatment options are still needed.”
Betsy Goodfellow
Related Content
Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals
Eli Lilly and Nexus Pharmaceuticals have announced that they have entered into a definitive agreement …
GSK’s Jemperli accepted for FDA review for endometrial cancer treatment
GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental …
GSK shares results from phase 3 trial for gonorrhoea treatment
GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential …